Relief Therapeutics Holding (Relief Therapeutics Holding) Net Change in Cash

: $-18.57 Mil (TTM As of Jun. 2023)

View and export this data going back to 1990. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Relief Therapeutics Holding's Net Change in Cash for the six months ended in Jun. 2023 was $-7.16 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was $-18.57 Mil.

Relief Therapeutics Holding Net Change in Cash Historical Data

The historical data trend for Relief Therapeutics Holding's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

0.13

-0.13

48.42

1.74

-27.40

Relief Therapeutics Holding Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Change in Cash																-21.96	23.39	-15.35	-11.42	-7.16

Relief Therapeutics Holding Net Change in Cash Calculation

Relief Therapeutics Holding's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-25.897	+	-8.586	+	6.888	+	0.198
	=	-27.40

Relief Therapeutics Holding's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -11.624 + -0.244 + 4.636 + 0.074

= -7.16

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-18.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relief Therapeutics Holding Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Relief Therapeutics Holding's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Net Change in Cash

Comparable Companies

XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN XSWX:KNRS XSWX:NWRN XSWX:MOLN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY

Traded in Other Exchanges

RLFTY:USA RLFz:UK RLF:Switzerland

Address

Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines

From GuruFocus

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements
By ACCESSWIRE ACCESSWIRE • 11-14-2022

Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
By ACCESSWIRE • 09-01-2023

Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
By ACCESSWIRE • 12-05-2023

Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa
By ACCESSWIRE ACCESSWIRE • 02-14-2023

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
By ACCESSWIRE ACCESSWIRE • 03-18-2023

Relief Therapeutics to Participate in January Investor Meetings
By ACCESSWIRE ACCESSWIRE • 12-14-2022

Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
By ACCESSWIRE ACCESSWIRE • 04-17-2023

Relief Therapeutics Announces Issuance of Shares from Authorized Capital
By ACCESSWIRE ACCESSWIRE • 12-13-2022

Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
By ACCESSWIRE ACCESSWIRE • 04-28-2023

RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement
By ACCESSWIRE ACCESSWIRE • 10-26-2022